Holen Sie sich die Stockscreener-App
1.49
6.43%
0.09
Handel nachbörslich:
1.52
0.03
+2.01%
Schlusskurs vom Vortag:
$1.40
Offen:
$1.44
24-Stunden-Volumen:
3.03M
Relative Volume:
1.10
Marktkapitalisierung:
$106.11M
Einnahmen:
$391.70K
Nettoeinkommen (Verlust:
$-52.34M
KGV:
-1.9867
EPS:
-0.75
Netto-Cashflow:
$-45.92M
1W Leistung:
+14.62%
1M Leistung:
-8.59%
6M Leistung:
+422.26%
1J Leistung:
+41.90%
1-Tages-Spanne:
$1.42
$1.555
1-Wochen-Bereich:
$1.21
$1.555
52-Wochen-Spanne:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Vergleichen Sie OVID mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.49 | 99.70M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Historical volatility pattern of Ovid Therapeutics Inc. visualizedWeekly Investment Summary & Free High Accuracy Swing Entry Alerts - newser.com
Leerink Partners Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
OVID: Leerink Partners Initiates Coverage with 'Outperform' Rati - GuruFocus
Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target - MarketScreener
Can trapped investors hope for a rebound in Ovid Therapeutics Inc.2025 Market Sentiment & Daily Stock Trend Reports - newser.com
Ovid Therapeutics (OVID) Receives Positive Outlook from Analyst - GuruFocus
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsMarket Activity Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-16 07:02:40 - newser.com
Price to book ratio of Ovid Therapeutics Inc. – HAM:1OT - TradingView
Published on: 2025-11-14 21:11:45 - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationWeekly Profit Summary & Real-Time Buy Signal Notifications - newser.com
Is Ovid Therapeutics Inc. stock oversold or undervaluedPortfolio Update Report & Community Driven Trade Alerts - Fundação Cultural do Pará
Ovid Therapeutics Draws Strong Buy Ratings After Q3 Earnings Update - Finimize
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):